Prognostic value of MMP-2 for patients with ovarian epithelial carcinoma: a systematic review and meta-analysis
- 259 Downloads
The reported roles of matrix metalloproteinase 2 (MMP-2) on the prognosis of patients with epithelial ovarian cancers (EOCs) are inconsistent.
This meta-analysis was performed to evaluate the prognostic significance of MMP-2 for patients with EOCs by analyzing 11 studies.
We systematically searched articles in the Cochrane Library, Pubmed, Embase, China National Knowledge Infrastructure (CNKI), Wanfang Database, and Chinese Biological Medical (CBM) Database, updated to February 1st 2015, with the following search terms: ovarian neoplasm OR ovarian tumor OR ovarian carcinoma OR ovarian malignance OR ovarian cancer AND matrix metalloproteinase-2 OR MMP-2.
A total of 11 studies involving 1058 patients with EOCs were in accordance with the inclusion criteria. The pooled HR was 1.09 (95% CI 0.32–1.86, p = 0.006) in patients with overexpression of stromal MMP-2 with significant heterogeneity (I 2 = 53.1%, p = 0.074) between studies. For patients with MMP-2 overexpression in tumor cells, the pooled HR was 1.42 (95% CI 1.14–1.70, p = 0.000) with no significant heterogeneity (I 2 = 43.4%, p = 0.078) between studies. Sensitivity analyses were stable.
MMP-2 overexpression in tumor cells rather than stroma was significantly associated with poor prognosis in patient with endothelial ovarian cancer; however, the result remains to be confirmed with additional high-quality studies.
KeywordsMeta-analysis MMP-2 Ovarian epithelial carcinoma Prognostic value
The study was supported by the National Natural Science Foundation of China (No. 81301556).
Compliance with ethical standards
Conflict of interest
All authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of Shandong Provincial Hospital Affiliated to Shandong University and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 1.American Cancer Society (2015) Cancer facts and figures 2015. American Cancer Society, AtlantaGoogle Scholar
- 7.Pan Y, Zhu D, Si WN et al (2008) Expressions of RhoC and MMP-2 proteins in epithelial ovarian cancer tissues and their clinical significances. J Jilin Univ Medicine Edition) 34:1042–1045Google Scholar
- 10.Horner MJ, Ries LAG, Krapcho M et al (2009) SEER Cancer Statistics Review, 1975–2006, National Cancer Institute. In: Bethesda, MD (ed) SEER Cancer Statistics ReviewGoogle Scholar
- 12.Yu L, Wang WY, Gan HY et al (2011) Expression and clinical significance of MMP-2 and MMP-7 in ovarian carcinoma. Chinese J Histochem Cytochem 20:325–329Google Scholar
- 19.Wu DB, Yang J, Yao YL et al (2013) Expression and clinical significance of MMP-2 and MMP-7 in ovarian carcinoma. Proceed Clin Med 22:650–652Google Scholar
- 20.Wells G, Shea B, Peterson J et al (2000) The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 3rd symposium on systematic reviews: beyond the basics. pp 3–5Google Scholar
- 24.Wang XY, Zhang YK, Ren GH (2004) Relation between expression of MMP-2 and MMP-9 and invasion, metastasis of epithelial carcinoma of ovary. Chin J Oncol Rahabil 11:406–408Google Scholar